Celon Pharma Statistics

Total Valuation

Celon Pharma has a market cap or net worth of EUR 271.78 million. The enterprise value is 270.16 million.

Market Cap	271.78M
Enterprise Value	270.16M

Important Dates

The last earnings date was Wednesday, November 19, 2025.

Earnings Date	Nov 19, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	38.86M
Shares Outstanding	n/a
Shares Change (YoY)	-1.95%
Shares Change (QoQ)	-2.57%
Owned by Insiders (%)	0.01%
Owned by Institutions (%)	12.39%
Float	23.82M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.14
PB Ratio	2.98
P/TBV Ratio	3.00
P/FCF Ratio	n/a
P/OCF Ratio	2,451.76
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-9.42
EV / Sales	5.07
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-27.96

Financial Position

The company has a current ratio of 1.90, with a Debt / Equity ratio of 0.04.

Current Ratio	1.90
Quick Ratio	1.38
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	-0.34
Interest Coverage	-58.14

Financial Efficiency

Return on equity (ROE) is -27.03% and return on invested capital (ROIC) is -14.99%.

Return on Equity (ROE)	-27.03%
Return on Assets (ROA)	-12.84%
Return on Invested Capital (ROIC)	-14.99%
Return on Capital Employed (ROCE)	-26.86%
Revenue Per Employee	93,410
Profits Per Employee	-50,677
Employee Count	558
Asset Turnover	0.41
Inventory Turnover	2.82

Taxes

Income Tax	-950,307
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -19.38% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-19.38%
50-Day Moving Average	4.90
200-Day Moving Average	5.26
Relative Strength Index (RSI)	50.50
Average Volume (20 Days)	1

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Celon Pharma had revenue of EUR 52.87 million and -28.68 million in losses. Loss per share was -0.55.

Revenue	52.87M
Gross Profit	36.12M
Operating Income	-26.24M
Pretax Income	-29.63M
Net Income	-28.68M
EBITDA	-20.17M
EBIT	-26.24M
Loss Per Share	-0.55

Full Income Statement

Balance Sheet

The company has 4.93 million in cash and 3.33 million in debt, giving a net cash position of 1.60 million.

Cash & Cash Equivalents	4.93M
Total Debt	3.33M
Net Cash	1.60M
Net Cash Per Share	n/a
Equity (Book Value)	91.21M
Book Value Per Share	1.69
Working Capital	11.43M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 110,850 and capital expenditures -9.77 million, giving a free cash flow of -9.66 million.

Operating Cash Flow	110,850
Capital Expenditures	-9.77M
Free Cash Flow	-9.66M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 68.32%, with operating and profit margins of -49.63% and -54.25%.

Gross Margin	68.32%
Operating Margin	-49.63%
Pretax Margin	-56.05%
Profit Margin	-54.25%
EBITDA Margin	-38.14%
EBIT Margin	-49.63%
FCF Margin	n/a

Dividends & Yields

Celon Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.95%
Shareholder Yield	1.95%
Earnings Yield	-10.55%
FCF Yield	-3.56%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Celon Pharma has an Altman Z-Score of 9.12 and a Piotroski F-Score of 3.

Altman Z-Score	9.12
Piotroski F-Score	3